Valuation: Arcturus Therapeutics Holdings Inc.

Market Cap 409M 357M 336M 306M 575M 39.07B 575M 4.03B 1.55B 19.95B 1.53B 1.5B 64.33B P/E 2026 *
-4.23x
P/E 2027 * -3.94x
Enterprise Value 249M 218M 205M 187M 350M 23.81B 350M 2.45B 947M 12.16B 935M 915M 39.19B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 13.8x
Free-Float
92.01%
Yield 2026 *
-
Yield 2027 * -
09-18 Arcturus Therapeutics Holdings Inc Hosts Virtual Presentation On ARCT-810 Phase 2 Clinical Program And Provides Update On mRNA Liver Therapeutics Platform CI
09-09 Arcturus Therapeutics Holdings Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 09:20 AM
08-06 Arcturus Therapeutics Holdings Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-02 Arcturus Therapeutics Holdings Inc. And Thermo Fisher Scientific Inc. Announce Strategic Collaboration To Advance ARCT-032 For Cystic Fibrosis CI
07-02 Arcturus Therapeutics Shares Rise on Plans to Work with Thermo Fisher Scientific on Cystic Fibrosis Drug DJ
07-02 Arcturus Therapeutics, Thermo Fisher Scientific to Collaborate on Advancing ARCT-032 in Cystic Fibrosis MT
06-29 Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Small Cap Comp Growth Benchmark CI
06-29 Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark CI
06-29 Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2000 Growth Benchmark CI
06-29 Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000E Growth Benchmark CI
06-28 Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Microcap Growth Benchmark Index CI
06-28 Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000 Growth Benchmark CI
1 day-2.11%
1 week-9.22%
Current month-2.57%
1 month+6.91%
3 months+98.89%
6 months+116.89%
Current year+134.58%
1 week 13.88
Extreme 13.88
17.96
1 month 12.42
Extreme 12.42
17.96
Current year 5.5
Extreme 5.5
17.96
1 year 5.5
Extreme 5.5
24.17
3 years 5.5
Extreme 5.5
45
5 years 5.5
Extreme 5.5
53.68
10 years 4.11
Extreme 4.11
129.71
Manager TitleAgeSince
Chief Executive Officer 54 2013-02-28
Director of Finance/CFO 71 2026-04-30
Chief Tech/Sci/R&D Officer 65 -
Director TitleAgeSince
Chairman 83 2018-05-26
Director/Board Member 67 2018-05-26
Director/Board Member 67 2018-05-26
Date Insider Type Main position Quantity % Market Cap. Importance
5/1/26 Free

Chief Financial Officer

100,000 0.3683%
12/17/25 Free

Controller/Auditor

10,000 0.0368%
12/17/25 Free

General Counsel

54,000 0.1989%
Change 5-day change 1-year change 3-year change Capi.($)
-2.11%-9.22%-31.62%-47.21% 409M
-0.07%+7.14%+53.95%+111.00% 74.27B
+0.02%+0.80%+36.43%+79.25% 61.21B
+0.28%+5.73%+33.67%+20.82% 27.55B
-0.15%+0.75%-16.69%+361.67% 26.38B
+2.93%+4.32%+2.18%-3.60% 25.34B
+0.94%+3.93%+25.92%-8.85% 20.84B
-1.47%+4.86%-5.94%+519.63% 14.94B
+0.87%-3.73%+159.95%+327.53% 15.17B
+1.63%+2.20%+46.92%+170.72% 14.41B
Average +0.28%+1.93%+30.48%+153.10% 28.05B
Weighted average by Cap. +0.38%+3.42%+36.79%+135.85%

Financials

2026 *2027 *
Net sales 18.64M 16.29M 15.31M 13.97M 26.22M 1.78B 26.23M 184M 70.9M 910M 70M 68.46M 2.93B 29.58M 25.85M 24.3M 22.17M 41.62M 2.83B 41.62M 292M 113M 1.44B 111M 109M 4.66B
Net income -97.29M -85.02M -79.91M -72.92M -137M -9.3B -137M -959M -370M -4.75B -365M -357M -15.31B -113M -99.13M -93.17M -85.02M -160M -10.84B -160M -1.12B -431M -5.54B -426M -417M -17.85B
Net Debt -160M -140M -131M -120M -225M -15.27B -225M -1.57B -607M -7.8B -600M -587M -25.13B -
Logo Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
Employees
109
Date Price Change Volume
26-09-22 US$14.38 -2.11% 1,074,431
26-09-21 US$14.69 -8.36% 1,003,119
26-09-18 US$16.03 -5.32% 841,474
26-09-17 US$16.93 +8.53% 1,302,481
26-09-16 US$15.60 -1.52% 851,437
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
14.38USD
Average target price
22.30USD
Spread / Average Target
+55.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARCT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!